<PAGE> 1
- -------- ---------------------------
FORM 3 OMB APPROVAL
- -------- ---------------------------
OMB NUMBER 3235-0104
EXPIRES: SEPTEMBER 30, 1998
ESTIMATED AVERAGE BURDEN
HOURS PER RESPONSE .....0.5
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f)
of the Investment Company Act of 1940
<TABLE>
<S> <C> <C> <C>
- ------------------------------------------------------------------------------------------------------------------------------------
1. Name and Address of Reporting Person 2. Date of Event Requiring 4. Issuer Name and Ticker or 6. If Amendment, Date
Statement Trading Symbol of Original
(Month/Day/Year) (Month/Day/Year)
LIGAND PHARMACEUTICALS INCORPORATED
("LIGAND") 5-11-98 SERAGEN, INC. (SRGN)
- ---------------------------------------- ---------------------------- ---------------------------------- -----------------------
(Last) (First) (Middle) 3. IRS or Social Security 5. Relationship of Reporting 7. Individual or Joint/
Number of Reporting Person to Issuer Group Filing (Check
Person (Voluntary) (Check all applicable) Applicable Line)
10275 SCIENCE CENTER DR. [ ] Director [X] 10% Owner [X] Form filed by
- ---------------------------------------- [ ] Officer [ ] Other One Reporting
(Street) (give (specify Person
SAN DIEGO CA 92121 title below) below) [ ] Form filed by
- ---------------------------------------- More than One
(City) (State) (Zip) ---------------------------- Reporting Person
- ------------------------------------------------------------------------------------------------------------------------------------
TABLE 1 -- NON-DERIVATIVE SECURITIES BENEFICIALLY OWNED
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of Security 2. Amount of Securities 3. Ownership Form: 4. Nature of Indirect
(Instr. 4) Beneficially Owned Direct (D) or Beneficial
(Instr. 4) Indirect (I) Ownership (Instr. 5)
(Instr. 5)
- ------------------------------------------------------------------------------------------------------------------------------------
NO SECURITIES OWNED(1)
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one Reporting Person, see Instruction 4(b)(v).
(Over)
(Print or Type Responses) SEC 2270 (7-96)
</TABLE>
<PAGE> 2
FORM 3 (CONTINUED)
TABLE II -- DERIVATIVE SECURITIES BENEFICIALLY OWNED
(E.G., PUTS, CALLS, WARRANTS, OPTIONS, CONVERTIBLE SECURITIES)
<TABLE>
<S> <C> <C> <C> <C> <C>
- ------------------------------------------------------------------------------------------------------------------------------------
1. Title of Derivative Security 2. Date 3. Title and Amount of 4. Conver- 5. Owner- 6. Nature of Indirect
(Instr. 4) Exercisable and Securities Underlying sion or ship Beneficial Ownership
Expiration Date Derivative Security Exercise Form of (Instr. 5)
(Month/Day/ (Instr. 4) Price of Deriv-
Year) Deri- ative
vative Security:
Security
------------------------------------------------- Direct
Date Expira- Amount or (D) or
Exercis- tion Title Number Indirect (I)
able Date of Shares (Instr. 5)
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------------
</TABLE>
Explanation of Responses:
(1) Ligand has acquired voting power with respect to certain matters of shares
of common stock and preferred stock of Seragen, Inc. representing, on an
as-converted basis, 118,654,461 shares of common stock of Seragen, Inc.
through irrevocable proxies granted to Ligand by certain directors,
officers and stockholders of Seragen, Inc. Ligand does not have any
pecuniary interest in the shares.
** Intentional misstatements or omissions of facts constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, See Instruction 6 for procedure.
Ligand Pharmaceuticals Incorporated
By:
/s/ WILLIAM L. RESPESS May 21, 1998
- ----------------------------------- ------------
William L. Respess, Vice President, Date
General Counsel, Government Affairs
(Print or Type Responses) Page 2
SEC 2270 (7-96)
